Patient Evaluation: 
(Twenty lines not to exceed 75 character. ptr | ine | 
p 
Treat. 
-Every wnen w tsc count > l.u — 
2-3 davs everv 3 months in remission 
History, phys. exam 
X 
j 
CBC , differential 
and platelet counts 
X 
X X 
SMA12/PT/PTT/FIB/FSP 
and electrolytes* 
X 
X X 
BM aspirate & BX** 
X 
X 
BM cytogenetics 
X 
EKG/CXR/urinalysis* 
X 
Pulmonarv function test 
X 
* In addition as indicated by clinical and hematologic situations 
** Bone marrow aspirate and peripheral blood for PCR and functional evaluation 
of the MDR content of the cells at +21, +32 days post marrow reinfusion, and 
every three weeks during the first 6 months every 3 months during the first 
2 years, and every 6 months for the first 5 years following transplant. 
Miscellaneous Information: 
(Include any other information that you feel is pertinent to the study) 
(Three lines not to exceed 75 characters per line 
None 
Statistical Considerations: 
(Twelve lines not to exceed 75 characters per line 
We plan to initially study 15-20 advanced ovarian cancer patients in this pilot 
trial. We estimate that 100% of the patients will exhibit evidence of the 
functional MDR-1 sequences since chemotherapy selection in vivo will be used to 
select for the hematopoietic cells which have retained the MDR-1 retroviral 
transgenome . 
Objectives: 
(Twelve lines not to exceed 75 characters P» f llflt 
To evaluate the feasibility of introducing into early hematopoietic 
progenitor cells the MDR-1 cDNA in advanced ovarian cancer patients and 
thereby promoting the in vivo selection of genetically modified 
hematopoietic cells which are resistant to chemotherapy by virtue of having 
been transduced by the MDR-1 cDNA containing safety-modified retroviruses. 
2. To determine the toxicity of modifying stem cells with MDR viruses on 
hematopoietic function following and during transplant. 
[ 662 ] Recombinant DNA Research, Volume 17 
R 
